WO2000078352A1 - Procede d'administration de medicaments possedant une affinite de liaison aux proteines plasmatiques et preparation utilisee pour la mise en oeuvre dudit procede - Google Patents
Procede d'administration de medicaments possedant une affinite de liaison aux proteines plasmatiques et preparation utilisee pour la mise en oeuvre dudit procede Download PDFInfo
- Publication number
- WO2000078352A1 WO2000078352A1 PCT/JP2000/004039 JP0004039W WO0078352A1 WO 2000078352 A1 WO2000078352 A1 WO 2000078352A1 JP 0004039 W JP0004039 W JP 0004039W WO 0078352 A1 WO0078352 A1 WO 0078352A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- derivative
- plasma protein
- binding affinity
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
Definitions
- the present invention relates to a method for administering a drug which controls the amount of an active ingredient of a drug having a binding affinity to a plasma protein, and a preparation which controls the amount of an active ingredient of a drug having a binding affinity to a plasma protein.
- drugs administered for the purpose of treatment, diagnosis, etc. once undergo absorption, distribution, metabolism, excretion, etc., through the systemic blood circulation.
- drugs move along with the blood flow
- migration between the spaces in blood vessels, interstitial spaces, and cells occurs by diffusion and transport of free drugs that are not bound to proteins, etc., and reaches the target site of action.
- the concentration of free drug becomes uniform in each space, and the overall concentration pattern is determined by the degree of binding to proteins and the like. And some are reversibly bound to biological macromolecules such as plasma proteins.
- those that can penetrate capillary walls or cell membranes are non-binding drugs and can act as active ingredients Is It is a free drug that is not bound to plasma proteins, etc., and its transfer to the site of action is greatly affected by binding to plasma proteins, etc.
- 99m-technetium labeled mercapto ⁇ cetyl glycylglycylglycine (9 9 m Tc-MAG 3 ) is widely used in kidney scintigraphy one, in particular by connexion effective renal its tubular secretion and renal extraction may indicate the flow of plasma.
- 9 9 m Tc-MAG 3 in a concentration of the cross-sectional agent diagnosis is known that about 90% bound to plasma proteins (Bubeck B. et al., J. ..
- the concentration of the free drug in the blood can be maintained at a relatively low level over a long period of time, and a sustained onset of the drug effect may be achieved.
- an object of the present invention is to provide a method for appropriately administering a drug by controlling the binding of the drug to plasma protein, and at the same time, to provide a preparation capable of controlling the binding of the drug to plasma protein. According to the present invention, it has become possible to administer an appropriate drug based on the control of the binding of the drug to plasma proteins, and at the same time, it has become possible to provide a preparation that enables such an administration method.
- the present invention provides a method for administering a first drug having a binding affinity to a plasma protein, comprising administering a second drug having a binding affinity to a common plasma protein with the drug at the same time as or before or after the administration of the first drug.
- This is a method of administering a drug that has binding affinity for plasma protein, characterized in that the drug is administered to control the binding of the first drug to plasma protein.
- the first drug and the second drug when inhibiting the binding of the first drug to plasma protein, it is preferable that the first drug and the second drug have a binding affinity at a common binding site of the plasma protein.
- the timing of administration may be before, after, or simultaneously with the administration of the first drug, and is appropriately selected according to the timing at which the free concentration at which the appropriate effect of the first drug is obtained is obtained.
- One drug may be used, or multiple drugs may be used in combination if a synergistic effect is expected.
- the drug can be supplied as a preparation consisting of the first drug and the second drug.
- the first drug and the second drug can be filled into separate containers and made into a drug product.
- simultaneous administration by mixing at the time of use is possible, and the first drug and the second drug can be supplied. It is also possible to administer the drug at another time or by another route of administration. It may be.
- the radionuclide 1 Bok carbon 1.
- 15 - oxygen (1 5 0), 18 Fluorine (1 8 F)
- 32- phosphorus (3 2 P)
- 59 - iron (5 9 Fe)
- 67- copper (0/01)
- 67- gully um 'Ga
- 81m - krypton 8 1 m Kr
- 8 WINCH rubidium 8 iRb
- 89- scan Toronchimu 8 9 Sr
- 90- cum tri U beam 90 Y
- 99m- technetium 99m Tc
- 123- ® over de (1 23 1), 125-Yodo 25 1)
- 13 Bok Yodo 3 1 1) 117m- tin 1 7m Sn
- 153- summary um (1 Sm)
- 186- rhenium (1 8 6 Re)
- the compound such as a chelating group or a receptor ligand of the first drug labeled with the radionuclide is, for example, bisaminothiol or a derivative thereof, monoaminomonoamidebisthiol or a derivative thereof, bisamidobisthiol.
- a derivative thereof mercaptoacetyldaricylglycylglycine or a derivative thereof, hexamethylpropyleneamine oxime or a derivative thereof, ethylenebis [bis (2-ethoxyshethyl) phosphine] (tetrofosmin) or a derivative thereof, 2, 3 -Dimercaptosuccinic acid or its derivative, ethylene cysteine dimer derivative, methoxyisobutyl isonitrile derivative, polyamine derivative, pyridoxylidene aminate derivative, methylene diphosphonate, hydroxymethylene It is selected from phosphonate derivatives, 3-methyl- ⁇ -phenylpentadecanoic acid or its derivatives, ⁇ ⁇ ⁇ ⁇ ⁇ -isopropylamphetamine, hippuric acid, benzylguanidine, tropane derivatives and the like.
- the second drug is, for example, bucolome, cefazolin, etoposide, fenirbutazone, aspirin, salicylic acid, ceftriaxone, snorefamethisolone, vanoleproic acid, nabumetone, 6-methoxy-2-naphthylacetic acid, ibuprofen , Probenecid, dansyl-L-asparagine, verapamil or disopyramide.
- Figure 1 is a diagram showing the free fraction by substitution of human plasma protein binding 9 9111 Tc_ AG 3 is there.
- Figure 2 is a diagram showing the free fraction by substitution of rat plasma protein binding 9 9 m Tc-MAG 3.
- Figure 3 is a diagram showing a clearance in blood 9 9 m Tc-MAG 3 rats.
- Figure 4 is a diagram showing the release rate of 9 9 111 Tc-MAG 3 in rat blood.
- Figure 5 is a diagram showing the accumulation of 9 9 m Tc- MAG 3 to rat kidney.
- Figure 6 is a view to view the effect of bucolome loading on 9 9 m Tc- MAG 3 biodistribution of rats.
- FIG. 7 is a diagram showing a rat 99 m Tc_MAG 3 renogram.
- the first drug having the binding affinity to the plasma protein may be either a therapeutic drug or a diagnostic drug as long as it is a drug suited for the purpose of administration.
- the diagnostic purpose in order to obtain the aforementioned replacement effect, it has the same competitive binding affinity to plasma proteins as the first drug, and inhibits the first drug from binding to plasma proteins. It is preferable to select from those that increase the amount of drug released, those that have a common binding site to the first drug and the plasma protein, and that have a higher binding affinity. In order to achieve this goal, a drug with a higher effect can be selected from those that increase the plasma protein binding rate of the first drug by binding the second drug to plasma protein. No studies have elucidated the nature of the reduction effect, but for example, it is conceivable that such an effect may be manifested by a mechanism similar to the allosteric effect of the enzyme.
- Example 8 shows Drug combination increases plasma protein binding rate It was found.
- the mixed preparation with medical preparations such as pH control, inorganic salts for osmotic pressure control, and stabilizers for stabilizing each component. Acceptable components can be added.
- the mixed drug product can also be processed into appropriate dosage forms such as liquids and lyophilized drug products in consideration of the constituent components and storage stability. It is also possible to fill a separate container with the drug and the second drug and supply it as a formulated kit.
- each drug contains components that are permitted to be used for medical use, such as a stabilizing agent.
- the administration method of each drug It can be added, the administration method of each drug, It may be processed into an optimal formulation such as a liquid or lyophilized agent in consideration of qualitative properties.
- an optimal formulation such as a liquid or lyophilized agent in consideration of qualitative properties.
- the components are made into a kit in such a separate container, the first drug and the second drug are administered separately It is also possible to perform simultaneous administration by mixing at the time of use. In particular, if the first drug and the second drug are expected to change during long-term storage, etc.
- a kit prepared in a separate container and formulated is useful.
- plasma proteins to which the drug binds include human serum albumin (HSA), ⁇ -factory acid glycoprotein (AGP), ⁇ -globulin, and lipoprotein, but many bind to HSA or AGP.
- HSA human serum albumin
- AGP ⁇ -factory acid glycoprotein
- AGP ⁇ -globulin
- lipoprotein binds to HSA or AGP.
- the first drug has a binding affinity to HSA
- it is preferable to select an acidic drug having a binding affinity for HSA it is preferable to select an acidic drug having a binding affinity for HSA, and the first drug has a binding affinity for AGP.
- the first drug has a binding affinity for multiple plasma proteins, or different binding sites in a single protein, it is preferable to select a basic drug that binds to AGP. Combination of multiple drugs may be effective in cases where the drug has a binding affinity.
- the original pharmacology of the drug other than the binding affinity to the plasma protein described above Action is clinically acceptable It is
- the timing of administration of the second drug may be at the same time as, before, or after the administration of the first drug, and is appropriately selected so as to exert an effect in accordance with the purpose of administration of the first drug.
- the route of administration of the drug is appropriately selected from intravenous, intraarterial, subcutaneous, lymphatic, and oral routes.
- the binding sites for HSA include site I, site II, and site II.
- bucolome (5-n-butyl-l-cysteine) is used.
- Clohexyl -2,4,6-trioxoperhydropropyrimidine is used.
- cefazolin (7- [1- (H) -tetrazolylacetamide] -3- [2- (5-methyl-1,3,4- Thiazolyl) thiomethyl] -3-cef-4-carboxylate
- phenylbutazone (1,2-diphenyl-3,5-dioxo-4-n-butylvirazolidine
- valproic acid sodium 2-propylpentanoate
- Aspirin (2-Acetoxybenzoic acid
- Salicylic acid Hydroxybenzoic acid
- Ceftriaxone ((6R, 7R) -7- [2-Amino-4-thiazolyl] -2 -Methoxy
- the second drugs having binding specificity for AGP include disopyramide (hi- (2-diisopropylaminoethyl) -hi-phenyl-2-pyridineacetamide) and verapamil (hi- [3- [ [2- (3,4-Dimethoxyphenyl) ethyl] -methylamino] propyl] -3,4-Dimethoxy- ⁇ - ( ⁇ -methylethyl) benzeneacetonitrile), propranolol (1-isopropylamino -3-(1-Naphthyloxy) -2-propanol).
- Radiotherapy for internal use which is labeled with a radionuclide and has binding affinity to plasma proteins.
- the drug or diagnostic agent compound and a chelating group or a receptor ligand for example, mercapto ⁇ cetyl Dali sill Dali sill Dali Singh (MAG 3) or a derivative thereof, to hexa-methylpropylene amine O oxime (HMPA0) or a derivative thereof , Ethylene bis [bis (2-ethoxyshethyl) phosphine] (tetrofosmin) or its derivative, 2,3-dimercaptosuccinic acid (DMSA) or its derivative, ⁇ , ⁇ '-ethylene-L-cysteine getyl ester Ethylene cysteine dimer (ECD) derivative, methoxytisobutylisonitrile (II) derivative, polyamine derivative such as diethylenetriaminepentaacetic acid (DTPA), pyridoxylidenamine derivative such as pyridoxyleneoleucine, and other methylene diphosphonate (MDP) , Hydroxymethylene diphospho
- IMP iodohippuric acid (0IH), 3-odobenzinoleguanidine (MIBG), N- (3-phenylenopropyl) -2j3-carbomethoxy-3j3- (4-odophenyl) north
- tropane derivatives such as pan (FP-CIT) and N-methyl-23-carboxy-33- (4-odophenyl) north-mouth bread (CIT).
- Radionuclides include 11-carbon ⁇ ), 15 oxygen (1 5 0), 18 fluorine (1 8 F), 32 - phosphorus (3 2 P), 59-iron (59 Fe), 67- copper (6 7 Cu), 67- gallium (67 Ga ), 81m- krypton (8 lm Kr), 81- rubidium (8 1 Rb), 89- scan Toronchimu (8 9 Sr), 90- cum thorium (90 Y), 99m - technetium (9 9m Tc), 111- Inn Indium (1 1 1 In), 123- Yodo 2 "I), 125- Yodo (1" I), 131- Yodo (1 ° 1 1), 133- key senones (1 3 3 Xe), 117m- tin ⁇ 1 7m Sn), 153- summary Umm (1 Li "Sm), 186- Leni ⁇ -time (1 8 6 re), 188- rhenium °.
- MAG 3 of 99m- technetium complexes (9 9m Tc-MAG 3) is to have an integrated property to the kidney, the in-vivo radiopharmaceuticals widely used for diagnostic purposes of renal and urinary tract disorders.
- 9 9m Tc-MAG 3 has been known that approximately 90% to plasma proteins is bound les, . That Therefore, using the sera except the blood cells and blood coagulation factors such as plasma proteins, 9 9 m Tc - the MAG 3 as a first agent, a drug agent with binding affinity with several serum proteins second In vitro experiments were carried out with the addition of bucolome, valproic acid, perlfalin, etc. as a result.
- 9 9 free ratio of m Tc-MAG 3 has increased, especially when using bucolome, 9 9 m Tc-free fraction of the MAG 3 has increased a place (Table 1), bucolome was 20 mg / kg load shown accumulation of 9 9 m Tc- MAG 3 to kidney case of rats 5, rats were administered bucolome 100 mg / kg in 9 9 m Tc- MAG 3 administered 10 minutes before using, 9 9 m Tc-MAG 3 results of measuring the biodistribution after 10 minutes after administration of the Figure 6 Is. These results those showing that 9 9 m Tc-MAG 3 liberated by performing bucolome load is increased, the accumulation of the chestnut Aransu and kidneys from rapid blood occurs is there.
- Tio one Doanfuetamin 2 ⁇ I-IMP) were vitro port and in vivo experiments to prove the displacement effect for in vitro experiments
- a substitution effect was observed with the addition of perhalin and 6-methoxy-2-naphthylacetic acid (6-MNA), which have binding specificity for HSA, and verapamil, which has binding specificity for AGP (Example 5 and Table 9). Therefore, it was proved that the substitution effect was observed even when the first drug was an organic compound.
- All experimental animals were male Wistar rats (200-250 g). Prior to the experiment, the experimental animals were bred under a 12-hour light / dark cycle for one week. They were given free access.
- human serum or rat serum as a site-specific drug that specifically binds to the site I or site II of albumin, it is site-specific for site I.
- Ku Rupuro acid, Warufuarin, cefazolin was performed as ibuprofen, sodium octanoate, following replacement of 99 m Tc-MAG 3 bound to serum albumin with sodium Orein acid with specificity for the site II.
- the above-prepared serum has specific binding to HSA site I or site II.
- the site-specific drug was dissolved in methanol or water and added.
- a control solution prepared by adding only methanol or water to the serum prepared above was used.
- a fixed amount of 99 m was added to each sample.
- Tc-MAG 3 (approximately 740 kBq / 20 / x 1) was added, and a fixed amount (20-50 ⁇ 1) was collected from each sample and used as a sample before ultrafiltration. And subjected to ultrafiltration under the conditions of 1500 Xg for 10 minutes. Then, 20-50 ⁇ l was collected from each filtrate and used as a sample after ultrafiltration. Radioactivity (cpm) was measured, and the release rate (%) was calculated by the following formula.
- HSA Human serum ⁇ , 'min
- RSA Rat serum min
- Tc-MAG, free 15 included (X) e Tc-MAG, free mixed (X) Test concentration 200 t M 400 fi 200 i M 400 fi M Control 10.20K 24.79X
- Tc-MAG Distribution in the control group and the Bucolome load group.
- Tc-MAG 3 the (740kBq / 100 1) was administered from the tail vein Wistar rats, a predetermined time (2, 5, 10, 15 minutes) were decapitated sacrificed, the organs while collecting blood The radioactivity was measured after excising and weighing the radioactivity. After correcting the half-life of radioactivity, the accumulation rate in each organ (% dose / organ and% dose / g tissue) was determined.
- Bucolome loading group 9 9 1 "-3 ⁇ 4 ⁇ 6 3 a bucolome to 5 minutes before administration 20 mg / kg body weight or was administered from tail vein as a 100 mg / kg body weight.
- the measurement results are in Table 2, Table 3 The results are shown in Tables 4 and 5 (above 20col / kg load) and Table 6 (100col / kg load).
- the sacrifice time point was set to 2, 5, and 10 minutes, and administration and sacrifice were performed under the same conditions as other dose settings, etc., and 3-5 mL of blood per rat was used. collected. with blood collection tube to separate the serum was determined free fraction according to the method of subsequent example 1 described. the percentage of free 9 9 m Tc- MAG 3 in rat blood in each time point in FIG. 4 Show.
- Control unit 170 0.941
- Example 4 Plasma protein binding 9 9 m Tc-ECD Human serum and HSA binding site
- Site-specific bucolome, valproic acid, perhalin, cefazolin, site II-specific ibuprofen, sodium octanoate, and binding sites not identified but specific for HSA with etoposide with sex it was studied displacement effect in the same manner as in example 1. the results are shown in Table 8.
- human serum controls opening Lumpur in 9 9 m Tc-ECD free fraction (26. against 0.3%), etoposide also 9 9 m Tc at any test concentration of 200 / z M and 400 ju M -. significantly increased the release rate of the ECD bucolome, valproic acid, a free fraction in Warufuarin There was no clear increase in the release rate for site-specific ibuprofen and octanoic acid.
- Example 5 Investigation of the Substitution Effect of Plasma Protein-bound 12 ° I-IMP 1: Investigation with a Single Agent Human serum and the second agent HSA as a second agent, bucolome specific to the binding site site I, perphalin, site Using ibuprofen, sodium octoate, 6-methoxy-2-naphthylacetic acid (6-MNA), and AGP-specific verapamil, which were specific to II, the replacement effect was examined in the same manner as in Example 1.
- the test concentration of the second drug (bucolome, etc.) was only 400 ⁇ , and the addition amount of 123 3 - ⁇ was about 220 kBq / 20/1. Table 9 shows the results.
- iI-IMP has binding sites for both albumin and AGP, and that it is possible to increase the rate of release with drugs specific for the binding site on each protein.
- Example 6 Plasma protein binding 1 2 3 Examination of displacement effect of I-IMP 2: specific for the binding site site II of HSA as study human serum and the second drug synergy 6 - MNA, the AGP specificity Similarly the specific verapamil and Yore , example 5, a test concentration of the second agent 400 mu Micromax, was examined displacement effect the amount of 1 2 3 I- IMP as about 220kBq / 20 1. the time , 6-MNA and verapamil were separately treated, and both were treated simultaneously. The presence of a synergistic effect was investigated. When both were treated simultaneously, the test concentration was 400 ⁇ . Table 10 shows the results.
- verapamil bulk powder 35 mg was dissolved in 2 ml of Vasolan injection (verapamil 5 mg / 2 ml, Eisai), and 1 ⁇ -IMP injection (ll lMBq / ml, Nippon Mediphysix) 34 1 was mixed and mixed well. .
- I-IMP Injection solution diluted with physiological saline to controls group rats (185kBq / 300 ⁇ 1) was administered through the tail vein, a predetermined time (2, 5, 10, 30, 60 minutes) After decapitation and sacrifice. Blood was collected, and at the same time, each organ was excised and weighed. Then, the radioactivity of the blood and each organ was measured. The half-life of radioactivity was corrected, and the accumulation rate of each organ (% .
- Example 8 Examination of control of the release ratio of I-FP-CIT Human serum and second drug, bucolome, fenirbutazone, perhalin, dansyl-L-asparagine (DNSA) specific for site I binding site of HSA, ibuprofen specific for site II, 6-MNA having conducted an experiment in the same manner as in example 5 using. test concentration of the second agent (bucolome, etc.) and only the addition amount of 1 2 5 I-FP-CIT was about 741 ⁇ (3/20 1 Table 15 shows the results.
- DNSA dansyl-L-asparagine
- DNSA can significantly reduce the free proportion of 1 2 5 I-FP-CIT . Also in Fuenirubutazon and I Bupurofen these results indicate that the release rate of the first drug can be reduced by the second drug having a binding affinity for plasma proteins.
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/018,745 US7029653B1 (en) | 1999-06-21 | 2000-06-21 | Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method |
EP00940773A EP1197227B9 (en) | 1999-06-21 | 2000-06-21 | Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method |
JP2001504414A JP4343473B2 (ja) | 1999-06-21 | 2000-06-21 | 血漿蛋白質に結合親和性を有する薬剤の投与方法並びに当該投与方法に用いられる製剤 |
CA2376159A CA2376159C (en) | 1999-06-21 | 2000-06-21 | Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method |
DE60036382T DE60036382T4 (de) | 1999-06-21 | 2000-06-21 | Verfahren zur Verabreichung von Arzneimitteln mit Bindungsaffinität zu Plasmaprotein und Präparat zur Verwendung in dem Verfahren |
DE60036382A DE60036382D1 (de) | 1999-06-21 | 2000-06-21 | Verfahren zur verabreichung von arzneimitteln mit bindungsaffinität zum plasmaprotein und verwendung der zusammensetzung in dem verfahren |
US11/353,152 US20060140857A1 (en) | 1999-06-21 | 2006-02-14 | Method of the administration of drugs with binding affinity for plasma protein and preparation to be used in the method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11/173514 | 1999-06-21 | ||
JP17351499 | 1999-06-21 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/353,152 Division US20060140857A1 (en) | 1999-06-21 | 2006-02-14 | Method of the administration of drugs with binding affinity for plasma protein and preparation to be used in the method |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000078352A1 true WO2000078352A1 (fr) | 2000-12-28 |
Family
ID=15961945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/004039 WO2000078352A1 (fr) | 1999-06-21 | 2000-06-21 | Procede d'administration de medicaments possedant une affinite de liaison aux proteines plasmatiques et preparation utilisee pour la mise en oeuvre dudit procede |
Country Status (8)
Country | Link |
---|---|
US (2) | US7029653B1 (ja) |
EP (1) | EP1197227B9 (ja) |
JP (1) | JP4343473B2 (ja) |
AT (1) | ATE372785T1 (ja) |
CA (1) | CA2376159C (ja) |
DE (2) | DE60036382T4 (ja) |
ES (1) | ES2290042T3 (ja) |
WO (1) | WO2000078352A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004024188A1 (ja) * | 2002-09-12 | 2004-03-25 | Nihon Medi-Physics Co., Ltd. | 薬物の血漿蛋白質結合を制御するための製剤 |
WO2004040309A1 (ja) * | 2002-10-31 | 2004-05-13 | Nihon Medi-Physics Co., Ltd. | 薬物の血漿蛋白結合における血漿蛋白質上の結合部位の測定法及び血漿蛋白質変異の測定法 |
CN117030905A (zh) * | 2023-10-09 | 2023-11-10 | 成都华西海圻医药科技有限公司 | 一种快速定量血浆中丁二酮浓度的lc-ms/ms分析方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2290042T3 (es) * | 1999-06-21 | 2008-02-16 | Nihon Medi-Physics Co., Ltd. | Metodo de administracion de farmacos con afinidad de union a proteina plasmatica y preparacion para ser usada en el metodo. |
GB0427392D0 (en) * | 2004-12-15 | 2005-01-19 | Amersham Plc | Stabilised 99mTc compositions |
US9321095B2 (en) | 2010-06-30 | 2016-04-26 | General Electric Company | Apparatuses and methods for cutting porous substrates |
US20160251261A1 (en) * | 2014-03-13 | 2016-09-01 | Stevanato Group International A.S. | Method of Handling a Liquid Drug Formation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4520112A (en) * | 1983-03-09 | 1985-05-28 | The Johns Hopkins University | Assay method for organic calcium antagonist drugs and a kit for such an assay |
US4642284A (en) * | 1983-06-13 | 1987-02-10 | Scripps Clinic And Research Foundation | Method and system for detection of complement pathway activation |
US4976950A (en) | 1988-12-19 | 1990-12-11 | The Dow Chemical Company | Bone marrow suppressing agents |
US5792444A (en) | 1989-05-09 | 1998-08-11 | The General Hospital Corporation | Labeled chemotactic peptides to image focal sites of infection or inflammation |
US6022541A (en) * | 1991-10-18 | 2000-02-08 | Beth Israel Deaconess Medical Center | Immunological preparation for concurrent specific binding to spatially exposed regions of vascular permeability factor bound in-vivo to a tumor associated blood vessel |
ATE314843T1 (de) * | 1996-03-12 | 2006-02-15 | Pg Txl Co Lp | Wasserlösliche paclitaxel-prodrogen |
DE19648629A1 (de) * | 1996-11-12 | 1998-05-14 | Meisegeier Bernhard Dr | Verfahren zur immunologischen Erfassung und Produktion von Antikörpern |
ES2290042T3 (es) * | 1999-06-21 | 2008-02-16 | Nihon Medi-Physics Co., Ltd. | Metodo de administracion de farmacos con afinidad de union a proteina plasmatica y preparacion para ser usada en el metodo. |
-
2000
- 2000-06-21 ES ES00940773T patent/ES2290042T3/es not_active Expired - Lifetime
- 2000-06-21 CA CA2376159A patent/CA2376159C/en not_active Expired - Fee Related
- 2000-06-21 EP EP00940773A patent/EP1197227B9/en not_active Expired - Lifetime
- 2000-06-21 DE DE60036382T patent/DE60036382T4/de not_active Expired - Lifetime
- 2000-06-21 DE DE60036382A patent/DE60036382D1/de not_active Expired - Lifetime
- 2000-06-21 WO PCT/JP2000/004039 patent/WO2000078352A1/ja active IP Right Grant
- 2000-06-21 JP JP2001504414A patent/JP4343473B2/ja not_active Expired - Fee Related
- 2000-06-21 US US10/018,745 patent/US7029653B1/en not_active Expired - Fee Related
- 2000-06-21 AT AT00940773T patent/ATE372785T1/de not_active IP Right Cessation
-
2006
- 2006-02-14 US US11/353,152 patent/US20060140857A1/en not_active Abandoned
Non-Patent Citations (8)
Title |
---|
ABDEL-RAHMAN M. ET AL.: "Interaction between verapamil and vincristine binding to plasma proteins", INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY, THERAPY AND TOXICOLOGY, vol. 30, no. 11, 1992, pages 536 - 537, XP002932507 * |
BRIAND C. ET AL.: "Study of the interaction between human serum albumin and some cephalosporins", MOL. PHARMACOL., vol. 21, no. 1, 1982, pages 92 - 99, XP002932504 * |
BUBECK BERND ET AL.: "Pharmacokinetics of technetium-99m-MAG3 in humans", THE JOURNAL OF NUCLEAR MEDICINE, vol. 31, no. 8, 1990, pages 2285 - 1293, XP002932508 * |
IVARSEN,PER RAMLOEV ET AL.: "Displacement of bilirubin from adult and newborn serum albumin by a drug and fatty acid", DEV. PHARMACOL. THER., vol. 12, no. 1, 1989, pages 19 - 29, XP002932503 * |
KAWAI K. ET AL.: "Competitive displacement of 99mTc-MAG3 serum protein binding in in-vitro and in-vivo", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 42, no. SUPPL. 1, June 1999 (1999-06-01), pages S584 - S586, XP002932501 * |
LOCKWOOD,GRAHAM F. ET AL.: "Pharmacokinetics of ibuprofen in man-III: Plasma protein binding", J. PHARMACOKINET. BIOPHARM., vol. 11, no. 5, 1983, pages 469 - 482, XP002932506 * |
MATSUI,M. ET AL.: "Application of fractional uptake method to 99mTc-ECD SPECT for quantification of brain perfusion using cardiac output index", KOBE DAIGAKU IGAKUBU KIYO (DEPARTMENT OF RADIOLOGY, KOBE UNIVERSITY SCHOOL OF MEDICINE), vol. 58, no. 4, 1998, pages 191 - 196, XP002932502 * |
SEMMES,ROBIN L.O. ET AL.: "Nonlinear binding of valproic acid (VPA) and E-delta2-valproic acid to rat plasma proteins", PHARM. RES., vol. 7, no. 5, 1990, pages 461 - 467, XP002932505 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004024188A1 (ja) * | 2002-09-12 | 2004-03-25 | Nihon Medi-Physics Co., Ltd. | 薬物の血漿蛋白質結合を制御するための製剤 |
JPWO2004024188A1 (ja) * | 2002-09-12 | 2006-01-05 | 日本メジフィジックス株式会社 | 薬物の血漿蛋白質結合を制御するための製剤 |
WO2004040309A1 (ja) * | 2002-10-31 | 2004-05-13 | Nihon Medi-Physics Co., Ltd. | 薬物の血漿蛋白結合における血漿蛋白質上の結合部位の測定法及び血漿蛋白質変異の測定法 |
US7175991B2 (en) | 2002-10-31 | 2007-02-13 | Nihon Medi-Physics Co., Ltd. | Method of measuring binding site on plasma protein of plasma protein-binding drug and method of measuring plasma protein mutation |
CN117030905A (zh) * | 2023-10-09 | 2023-11-10 | 成都华西海圻医药科技有限公司 | 一种快速定量血浆中丁二酮浓度的lc-ms/ms分析方法 |
CN117030905B (zh) * | 2023-10-09 | 2024-01-05 | 成都华西海圻医药科技有限公司 | 一种快速定量血浆中丁二酮浓度的lc-ms/ms分析方法 |
Also Published As
Publication number | Publication date |
---|---|
US7029653B1 (en) | 2006-04-18 |
US20060140857A1 (en) | 2006-06-29 |
ES2290042T3 (es) | 2008-02-16 |
JP4343473B2 (ja) | 2009-10-14 |
CA2376159C (en) | 2010-09-14 |
EP1197227A4 (en) | 2002-12-04 |
DE60036382T4 (de) | 2008-09-25 |
EP1197227B1 (en) | 2007-09-12 |
ATE372785T1 (de) | 2007-09-15 |
CA2376159A1 (en) | 2000-12-28 |
DE60036382D1 (de) | 2007-10-25 |
DE60036382T2 (de) | 2008-06-12 |
EP1197227A1 (en) | 2002-04-17 |
EP1197227B9 (en) | 2008-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA037778B1 (ru) | Меченые ингибиторы простатического специфического мембранного антигена (псма), их применение в качестве агентов для визуализации и фармацевтических агентов для лечения рака предстательной железы | |
Hagan et al. | Preparation and characterisation of vandetanib-eluting radiopaque beads for locoregional treatment of hepatic malignancies | |
JP2023107801A (ja) | 併用療法 | |
JP2013501224A (ja) | 葉酸を標的とした診断及び処置 | |
JP5642892B2 (ja) | 多形膠芽腫の治療のためのマシテンタンを含有する組み合わせ剤 | |
US20060140857A1 (en) | Method of the administration of drugs with binding affinity for plasma protein and preparation to be used in the method | |
JP2017503763A (ja) | Gcc発現細胞を撮像するための化合物及び組成物 | |
BR112021001148A2 (pt) | soluções estáveis de complexo de radionuclídeo concentrado | |
JP2012527424A (ja) | イネカルシトールの新しい治療的使用 | |
Verburg et al. | Molecular nuclear therapies for thyroid carcinoma | |
JP2003504395A (ja) | 腎臓に有害な可能性のある分子の腎臓取り込みの阻害 | |
US20200353107A1 (en) | In vivo imaging of tumor infiltration leukocytes | |
JP4236050B2 (ja) | 薬物の血漿蛋白結合における血漿蛋白質上の結合部位の測定法及び血漿蛋白質変異の測定法 | |
WO2004024188A1 (ja) | 薬物の血漿蛋白質結合を制御するための製剤 | |
US20240050597A1 (en) | Radiolabelled alpha-v beta-3 and/or alpha-v beta-5 integrins antagonist for use as theragnostic agent | |
Martin-Higueras et al. | Multicenter Long-Term Real World Data on Treatment With Lumasiran in Patients With Primary Hyperoxaluria Type 1 | |
WO2022266354A1 (en) | Combination comprising a neurotensin receptor binding compound and napoli | |
WO2022266357A1 (en) | Combination comprising a neurotensin receptor binding compound and napox | |
WO2022261770A1 (en) | Combination comprising a neurotensin receptor binding compound and folfirinox | |
Shirakami | Radioactive Iodine | |
JP2005112750A (ja) | 腎臓トランスポーターによる薬物動態の制御方法および製剤 | |
US20020155576A1 (en) | Metal-chelated nucleic acid binding peptides for in vivo detection and therapy of disease | |
JPH09169668A (ja) | 治療剤 | |
JP2005535676A (ja) | 腫瘍の処置における放射免疫療法の効果の増強 | |
US20100104511A1 (en) | Methods and compositions using chelator-antibody conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 504414 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref document number: 2376159 Country of ref document: CA Ref country code: CA Ref document number: 2376159 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10018745 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000940773 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000940773 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000940773 Country of ref document: EP |